Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project

Tessa Timmers, Rik Ossenkoppele, Sander C. J. Verfaillie, Chris W. J. van der Weijden, Rosalinde E. R. Slot, Linda M. P. Wesselman, Albert D. Windhorst, Emma E. Wolters, Maqsood Yaqub, Niels D. Prins, Adriaan A. Lammertsma, Philip Scheltens, Wiesje M. van der Flier, Bart N. M. van Berckel

Research output: Contribution to journalArticleAcademicpeer-review


We examined the relationships between amyloid-β PET and concurrent and longitudinal cognitive performance in 107 cognitively normal individuals with subjective cognitive decline (age: 64 ± 8 years, 44% female, Mini-Mental State Examination score 29 ± 1). All underwent 90-minute dynamic [ 18 F]florbetapir PET scanning and longitudinal neuropsychological tests with a mean follow-up of 3.4 ± 3.0 years. Receptor parametric mapping was used to calculate [ 18 F]florbetapir binding potential (BP ND ), and we performed linear mixed models to assess the relationships between global [ 18 F]florbetapir BP ND and neuropsychological performance. Higher [ 18 F]florbetapir BP ND was related to lower concurrent Mini-Mental State Examination (β ± SE: −1.69 ± 0.63 p < 0.01) and to steeper rate of decline on tasks capturing memory (Rey Auditory Verbal Learning Task immediate [β ± SE −1.81 ± 0.81, p < 0.05] and delayed recall [β ± SE −1.19 ± 0.34, p < 0.01]), attention/executive functions (Stroop II [color] [β ± SE −0.02 ± 0.01, p < 0.05], Stroop III [word-color] [β ± SE −0.03 ± 0.02, p < 0.05]), and language (category fluency [β ± SE −0.04 ± 0.01, p < 0.01]). These findings suggest that higher amyloid-β load in cognitively normal individuals with subjective cognitive decline from a memory clinic is associated with lower concurrent global cognition and with faster rate of decline in a variety of cognitive domains.
Original languageEnglish
Pages (from-to)50-58
JournalNeurobiology of Aging
Publication statusPublished - 2019

Cite this